Patient Engagement Study with Participants with AATD
Research type
Research Study
Full title
A Patient Engagement Study to Provide Participants with the Opportunity to Become Familiar with the Clinical Trials Unit Environment and Establish a Clinical Baseline in Adult Participants with Alpha-1 Antitrypsin Deficiency (AATD) who are Considering Participation in Future Gene Editing Clinical Trials
IRAS ID
341549
Contact name
Ulrike Lorch
Contact email
Sponsor organisation
Beam Therapeutics Inc.
Duration of Study in the UK
2 years, 8 months, 2 days
Research summary
The study is being conducted to provide participants with the opportunity to become familiar with the clinical trials unit environment in adult participants with alpha-1 antitrypsin deficiency (AATD) who are considering participation in future gene editing clinical trials. The study will also allow participants to undergo a series of assessments to establish a clinical baseline (such as vital signs, ECGs, blood samples, lung function tests).
The study will take approximately a week to complete. The study consists of a 'Day 1' visit (which involves the informed consent process, unit tour and clinical assessments) and a follow-up phone call with a Research Physician a week after the Day 1 visit. The Day 1 visit may be completed over multiple days (if required).
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
24/WM/0077
Date of REC Opinion
11 Apr 2024
REC opinion
Further Information Favourable Opinion